Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)
China · Delayed Price · Currency is CNY 4.200
+0.110 (2.69%)
Apr 29, 2026, 3:14 PM CST
SHE:300267 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,060 | 1,166 | 1,128 | 1,766 | 1,860 | 2,229 |
Other Revenue | - | - | 11.38 | 16.76 | 10.63 | 6.43 |
| 1,060 | 1,166 | 1,140 | 1,783 | 1,871 | 2,235 | |
Revenue Growth (YoY) | -12.96% | 2.30% | -36.09% | -4.67% | -16.32% | -6.17% |
Cost of Revenue | 773.41 | 857.49 | 849.75 | 1,501 | 1,460 | 1,916 |
Gross Profit | 286.19 | 308.27 | 289.86 | 281.73 | 410.79 | 319.44 |
Selling, General & Admin | 234.3 | 244.98 | 324.12 | 401.33 | 352.89 | 417.49 |
Research & Development | 44.17 | 45.07 | 45.17 | 57.44 | 48.15 | 49.02 |
Other Operating Expenses | 1.57 | 2.5 | 9.36 | 12.37 | 12.86 | 14.96 |
Operating Expenses | 280.03 | 292.56 | 380.04 | 464.81 | 421.45 | 469.93 |
Operating Income | 6.16 | 15.71 | -90.18 | -183.08 | -10.65 | -150.49 |
Interest Expense | -2.38 | - | -8.68 | -6.66 | -5.84 | -9.29 |
Interest & Investment Income | - | - | 4.73 | 9.59 | 7.17 | 20.65 |
Currency Exchange Gain (Loss) | - | - | -5.68 | 3.72 | -8.44 | 1.98 |
Other Non Operating Income (Expenses) | -8.9 | -4.01 | 10.79 | -31.86 | -0.57 | -5.42 |
EBT Excluding Unusual Items | -5.12 | 11.7 | -89.01 | -208.3 | -18.34 | -142.57 |
Impairment of Goodwill | - | - | - | -8.01 | - | -19.83 |
Gain (Loss) on Sale of Investments | -21.6 | -21.6 | -55.41 | -14.54 | 14.12 | - |
Gain (Loss) on Sale of Assets | 0.39 | 0.31 | 0.2 | 8.8 | 0.05 | 0.23 |
Asset Writedown | -357.83 | -358.23 | -237.41 | -12.91 | -0 | -683.35 |
Legal Settlements | - | - | -12.9 | - | - | -20.65 |
Other Unusual Items | - | - | 6.42 | 36.01 | 21.52 | 20.38 |
Pretax Income | -384.16 | -367.82 | -388.12 | -198.93 | 17.35 | -845.78 |
Income Tax Expense | 29.66 | 31.5 | 4.51 | 22.92 | -19.72 | -47.54 |
Earnings From Continuing Operations | -413.82 | -399.31 | -392.63 | -221.85 | 37.08 | -798.23 |
Minority Interest in Earnings | 19 | 19.49 | 19.26 | 26.53 | 8.87 | 7.03 |
Net Income | -394.82 | -379.82 | -373.37 | -195.32 | 45.94 | -791.2 |
Net Income to Common | -394.82 | -379.82 | -373.37 | -195.32 | 45.94 | -791.2 |
Shares Outstanding (Basic) | 2,058 | 2,063 | 2,063 | 2,063 | 2,060 | 2,063 |
Shares Outstanding (Diluted) | 2,058 | 2,063 | 2,063 | 2,063 | 2,060 | 2,063 |
Shares Change (YoY) | -0.15% | 0.01% | 0.01% | 0.11% | -0.11% | -0.04% |
EPS (Basic) | -0.19 | -0.18 | -0.18 | -0.09 | 0.02 | -0.38 |
EPS (Diluted) | -0.19 | -0.18 | -0.18 | -0.09 | 0.02 | -0.38 |
Free Cash Flow | 82.78 | 93.7 | -28.91 | -89.77 | 107.53 | -256.65 |
Free Cash Flow Per Share | 0.04 | 0.04 | -0.01 | -0.04 | 0.05 | -0.12 |
Dividend Per Share | - | - | - | - | 0.030 | - |
Gross Margin | 27.01% | 26.44% | 25.44% | 15.80% | 21.96% | 14.29% |
Operating Margin | 0.58% | 1.35% | -7.91% | -10.27% | -0.57% | -6.73% |
Profit Margin | -37.26% | -32.58% | -32.76% | -10.95% | 2.46% | -35.40% |
Free Cash Flow Margin | 7.81% | 8.04% | -2.54% | -5.03% | 5.75% | -11.48% |
EBITDA | 176.39 | 190.2 | 101.32 | 16.2 | 158 | 41.09 |
EBITDA Margin | 16.65% | 16.32% | 8.89% | 0.91% | 8.45% | 1.84% |
D&A For EBITDA | 170.24 | 174.49 | 191.5 | 199.27 | 168.66 | 191.59 |
EBIT | 6.16 | 15.71 | -90.18 | -183.08 | -10.65 | -150.49 |
EBIT Margin | 0.58% | 1.35% | -7.91% | -10.27% | -0.57% | -6.73% |
Revenue as Reported | - | - | 1,140 | 1,783 | 1,871 | 2,235 |
Advertising Expenses | - | - | 0.56 | 0.88 | 0.34 | 2.5 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.